Article
Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels.
PloS one - 1 Jan 2013
Stone Katie, Woods Emily, Szmania Susann M, Stephens Owen W, Garg Tarun K, Barlogie Bart, Shaughnessy John D, Hall Brett, Reddy Manjula, Hoering Antje, Hansen Emily, van Rhee Frits
Abstract excerpt
Multicentric Castleman Disease is largely driven by increased signaling in the pathway for the plasma cell growth factor interleukin-6. We hypothesized that interleukin-6/interleukin-6 receptor/gp130 polymorphisms contribute to increased interleukin-6 and/or other components of the interleukin-6 signaling pathway in HIV-negative Castleman Disease patients. The study group was composed of 58 patients and 50...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.